Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 462-469

  Sjögren, Sigrid ^a   Inganäs, Mats ^a   Lindgren, Anders ^a   Holmberg, Lars ^a   Bergh, Jonas ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL CYCLE S PHASE; DIAGNOSTIC VALUE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0344333420     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.462     Document Type: Article

References (32)

1. Coussens L, Yang-Feng TL, Liao Y-C, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncocgene. Science 230:1132-1139, 1985
2. Scheeler AC, Stern BF, Vaidyanathan L, et al: The neu oncogene: An erb-B-related gene encoding a 185,000Mr tumour antigen. Nature 312:513-516, 1984
3. Rajkumar T, Gullick WJ: The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 29:3-9, 1994
4. Zoll B, Kynast B, Corell B, et al: Alterations of the c-erbB2 gene in human breast cancer. J Cancer Res Clin Oncol 118:468-473, 1992
5. Yamashita H, Kobayashi S, Iwase H, et al: Analysis of oncogenes and tumor suppressor genes in human breast cancer. Jpn J Cancer Res 84:871-878, 1993
6. Duffy MJ: Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clin Biochem 26:439-447, 1993
7. Isola J, Visakorpi T, Holli K, et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
8. Tsuda H, Tsugane S, Fukutomi T, et al: Prognostic factors for recurrent breast cancer: Univariate and multivariate analyses including histologie grade and amplification of the c-erbB-2 proto-oncogene. Jpn J Clin Oncol 22:244-249, 1992
9. Prost S, Le MG, Douc-Rasy S, et al: Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer 58:763-768, 1994
10. Ji H, Lipponen P, Aaltomaa S, et al: c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res 13:1147-1152, 1993
11. Hartmann LC, Ingle JN, Wold LE, et al: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 74:2956-2963, 1994
12. Tang RP, Kacinski B, Validire P, et al: Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: A role for hematopoietic growth factor release by tumor cells? J Cell Biochem 44:189-198, 1990
13. Marx D, Schauer A, Reiche C, et al: c-erbB2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 116:15-20, 1990
14. Gusterson BA, Gelber RD, Goldhirsh A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group [see comments]. J Clin Oncol 10:1049-1056, 1992
15. Berns EMJJ, Klijn JGM, van Staveren IL, et al: Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: Correlation with steroid receptors. Eur J Cancer 28:697-700, 1992
16. Barbareschi M, Leonardi E, Mauri FA, et al: p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 98:408-418, 1992
17. Takahashi S, Narimatsu E, Asanuma H, et al: Immunohistochemical detection of estrogen receptor in invasive human breast cancer: Correlation with heat shock proteins, pS2 and oncogene products. Oncology 52:371-375, 1995
18. Carlomagno C, Perrone F, Gallo C, et al: c-erbE-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708, 1996
19. Wright C, Nicholson S, Angus B, et al: Relationship between c-erbb-2 protein product expression and response to adjuvant therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992
20. Borg Å, Baldetorp B, Fernö M, et al: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137-144, 1994
21. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
22. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1992
23. Bergh J, Norberg T, Sjögren S, et al: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1:1029-1034, 1995
24. Sjögren S, Inganäs M, Norbert T, et al: The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173-182, 1996
25. Rosai J: Breast, in Rosai J (ed): Ackerman's Surgical Pathology (ed 6). St Louis, MO, Mosby, 1981, pp 1087-1149
26. Liljegren G, Holmberg L, Adami H-O, et al: Sector resection with or without postoperative radiotherapy for stage I breast cancer: Five-year results of a randomized trial. Uppsala-Örebro Breast Cancer Study Group [see comment citations in Medline]. J Natl Cancer Inst 86:717-722, 1994
27. Holmberg L, Adami H-O, Lindgren A, et al: Prognostic significance of the Ackerman classification and other histopathological characteristics in breast cancer. APMIS 96:979-990, 1988
28. Christensen E: Multivariate survival analysis using Cox's regression model. Hepatology 7:1346-1358, 1987
29. Borg Å, Baldetorp M, Femö M, et al: ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137-143, 1991
30. Gullick WJ: New developments in the molecular biology of breast cancer. Eur J Cancer 26:509-510, 1990
31. Perren TJ: c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63:328-332, 1991
32. Tripathy D, Benz CC: Activated oncogenes and putative tumour suppressor genes involved in human breast cancers, in Benz CC, Liu ET (eds): Oncogenes and Tumor Suppressor Genes in Human Malignancies. Boston, MA, Kluwer Academic, 1993, pp 15-60